4 research outputs found
Evaluation of FDG-PET/CT Use in Children with Suspected Infection or Inflammation
[
18F]-FDG-PET/CT ([18F]-fluoro-deoxyglucose (FDG) positron emission
tomography/computed tomography (PET/CT)) is increasingly used as a diagnostic tool in
suspected infectious or inflammatory conditions. Studies on the value of FDG-PET/CT in children are
scarce. This study assesses the role of FDG-PET/CT in suspected infection or inflammation in children.
In this multicenter cohort study, 64 scans in 59 children with suspected infection or inflammation
were selected from 452 pediatric FDG-PET/CT scans, performed in five hospitals between January
2016 and August 2017. Main outcomes were diagnostic information provided by FDG-PET/CT for
diagnostic scans and impact on clinical management for follow-up scans. Of these 64 scans, 50
were performed for primary diagnosis and 14 to monitor disease activity. Of the positive diagnostic
scans, 23/27 (85%) contributed to establishing a diagnosis. Of the negative diagnostic scans, 8/21
(38%) contributed to the final diagnosis by narrowing the differential or by providing information
on the disease manifestation. In all follow-up scans, FDG-PET/CT results guided managemen
Increased Mortality in SDHB but Not in SDHD Pathogenic Variant Carriers
Germline mutations in succinate dehydrogenase subunit B and D (SDHB and SDHD) are
predisposed to hereditary paraganglioma (PGL) and pheochromocytoma (PHEO). The phenotype of
pathogenic variants varies according to the causative gene. In this retrospective study, we estimate
the mortality of a nationwide cohort of SDHB variant carriers and that of a large cohort of SDHD
variant carriers and compare it to the mortality of a matched cohort of the general Dutch population.
A total of 192 SDHB variant carriers and 232 SDHD variant carriers were included in this study.
The Standard Mortality Ratio (SMR) for SDHB mutation carriers was 1.89, increasing to 2.88 in carriers
affected by PGL. For SDHD variant carriers the SMR was 0.93 and 1.06 in affected carriers. Compared
to the general population, mortality seems to be increased in SDHB variant carriers, especially in
those affected by PGL. In SDHD variant carriers, the mortality is comparable to that of the general Dutch population, even if they are affected by PGL. This insight emphasizes the significance of
DNA-testing in all PGL and PHEO patients, since different clinical risks may warrant gene-specific
management strategies
Study protocol: A randomised controlled trial on the clinical effects of levothyroxine treatment for subclinical hypothyroidism in people aged 80 years and over
Background: Subclinical hypothyroidism is common in older people and its contribution to health and disease needs to be elucidated further. Observational and clinical trial data on the clinical effects of subclinical hypothyroidism in persons aged 80 years and over is inconclusive, with some studies suggesting harm and some suggesting benefits, translating into equipoise whether levothyroxine therapy provides clinical benefits. This manuscript describes the study protocol for the Institute for Evidence-Based Medicine in Old Age (IEMO) 80-plus thyroid trial to generate the necessary evidence base. Methods: The IEMO 80-plus thyroid trial was explicitly designed as an ancillary experiment to the Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism randomised placebo controlled Trial (TRUST) with a ne
Annales de droit commercial français, étranger et international / par M. E. Thaler
18891889 (A3).Appartient à l’ensemble documentaire : MAEDIGen0Appartient à l’ensemble documentaire : MAEDI01